The research team, led by surgeons from Zhongshan People’s Hospital and Shenzhen Longhua District People’s Hospital in China, analyzed 383 patients who underwent radical resection of solitary HCC with tumors no larger than 5 centimeters. Every patient had preoperative CTC testing performed three days before surgery, using a technique that combines negative immunomagnetic enrichment with immunofluorescence in situ hybridization. In this method, magnetic beads coated with antibodies against CD45—a marker found on white blood cells—are used to strip away leukocytes from a 5-milliliter peripheral blood sample, enriching the rare malignant cells that have entered the bloodstream through epithelial-mesenchymal transition. The remaining cells are then fixed on slides, hybridized with fluorescent probes targeting the centromeres of chromosomes 1 and 8, stained with DAPI, and counted under a fluorescence microscope. A count of one or more CTCs per sample defined CTC-positive status, a threshold the researchers found correlated strongly with microvascular invasion (MVI), the pathological hallmark of tumor aggressiveness in HCC.

The clinical significance of MVI cannot be overstated. From a pathological standpoint, an HCC lesion is not merely the visible tumor mass; it includes microscopic tumor cell nests invading nearby blood vessels, which a narrow resection margin cannot reliably remove. Previous studies have shown that wide margins reduce early postoperative recurrence in patients with MVI, but offer no such advantage in those without it. The problem has been that MVI can only be confirmed definitively after surgery, when the specimen is examined under a microscope—far too late to guide the surgeon’s hand. Imaging-based prediction models exist, but they lack standardized criteria and show limited accuracy, while subjective assessments such as tumor capsule integrity depend heavily on equipment quality and observer judgment. What the new study demonstrates is that CTC status, detectable in a simple blood draw, serves as a preoperative proxy for MVI, and when combined with tumor diameter measured on routine contrast-enhanced CT or MRI, it creates a decision framework that is both objective and minimally invasive.

The statistical architecture of the study was rigorous. All patients were stratified by tumor size (3 centimeters or less versus more than 3 centimeters) and CTC status (positive versus negative), then further divided by margin width—narrow margins defined as less than 1 centimeter and wide margins as 1 centimeter or more, based on the pathologist-reported shortest macroscopic distance from the tumor edge to the line of transection. Kaplan-Meier survival curves and log-rank tests compared recurrence-free survival (RFS) and overall survival (OS) between groups, while univariate and multivariate Cox regression models identified independent risk factors. A landmark analysis with a 24-month cutoff distinguished early from late recurrence, reflecting the understanding that early recurrences arise from residual microscopic disease while late recurrences more often represent de novo tumors in the diseased liver.

The results revealed a striking stratified effect. In the entire cohort, both tumor diameter and CTC status emerged as independent predictors of RFS and OS. But when the researchers drilled into tumor-size subgroups, something unexpected appeared. For patients with tumors 3 centimeters or smaller—179 patients in total—margin width had no effect on RFS or OS, regardless of CTC status. The MVI rate in this group was only 14.5 percent, and based on multicenter pathological data suggesting that MVI lesions extending more than 1 centimeter from the main tumor account for roughly 28 percent of all MVI in small HCC, the researchers calculated that MVI beyond the 1-centimeter threshold likely occurs in fewer than 4 percent of these patients. In other words, a narrow margin is almost always sufficient to clear the microscopic disease in small tumors, and pursuing wider excision offers no survival benefit while sacrificing liver tissue that cirrhotic patients need to preserve.

The picture changed dramatically for patients with tumors larger than 3 centimeters—204 patients in this subgroup. Here, the MVI rate jumped to 43 percent, consistent with prior findings that tumor size predicts both the incidence and the extent of vascular invasion. When the researchers stratified this group by CTC status, the effect of margin width split cleanly. Among CTC-negative patients with larger tumors, narrow and wide margins produced comparable RFS and OS, with no statistically significant difference. But among CTC-positive patients with tumors exceeding 3 centimeters, wide margins yielded significantly better RFS and OS than narrow margins. Moreover, the landmark analysis showed that wide margins in this CTC-positive subgroup specifically reduced early postoperative recurrence—recurrence within 24 months—while having no effect on late recurrence. This finding aligns precisely with the biological mechanism: early recurrences stem from minimal residual disease left behind at the resection margin, and in patients whose tumors are both large and shedding malignant cells into the bloodstream, that residual burden is substantial enough that only a wider excision can remove it.

The correlation between CTC status and MVI held across both tumor-size groups, reinforcing the biological plausibility of the framework. In patients with tumors 3 centimeters or smaller, the CTC-positive rate was 14.5 percent, and CTC-positive status correlated with MVI at a statistically significant level. In the larger-tumor group, the CTC-positive rate rose to 43.1 percent, and the correlation with MVI was even stronger. Notably, CTC status showed no significant association with other clinicopathological variables, including alpha-fetoprotein levels and tumor differentiation grade, suggesting that it captures a distinct dimension of tumor biology—specifically, the propensity for vascular invasion and hematogenous dissemination—that traditional serum markers and histological grading do not fully reflect.

The study’s authors frame their findings within the broader concept of precision medicine in hepatobiliary surgery. By identifying patients who do not need wide margins—those with small tumors regardless of CTC status, and those with larger tumors that are CTC-negative—surgeons can preserve more functional liver parenchyma, reducing the risk of postoperative liver failure and increasing the option of repeat resection or other multimodal therapies if recurrence does occur. Conversely, for the smaller subset of patients with large, CTC-positive tumors, the data argue for pursuing wide margins, or alternatively, for using preoperative adjuvant therapy to reduce tumor burden before attempting an extended resection. Both variables—CTC count from a peripheral blood draw and tumor diameter from standard cross-sectional imaging—are available before the operation, are objective, and involve minimal patient discomfort, making the framework readily implementable in clinical practice without specialized equipment beyond the CTC detection platform.

The researchers acknowledge important limitations. The retrospective design carries inherent biases and confounding factors that only a prospective study with a larger sample size can eliminate. The cohort was overwhelmingly Chinese and hepatitis B virus-related, raising questions about whether the conclusions apply to non-Asian populations or to patients with hepatitis C-related or alcohol-related HCC. CTC counts may fluctuate over time within the same patient, introducing temporal heterogeneity. The median follow-up of 30 months, while adequate for capturing early recurrence patterns, is insufficient for robust long-term overall survival conclusions beyond five years. And the cost of CTC detection remains high in some regions, though the authors expect this to decrease as detection methods improve. The findings also apply specifically to patients with solitary tumors no larger than 5 centimeters, the population in which the resection margin dilemma is most acute.

Despite these caveats, the study represents a meaningful advance in a field where the optimal margin width has been debated for decades without consensus. Previous attempts to stratify patients by tumor size alone produced contradictory results, with some groups reporting survival benefits from wide margins across all tumor diameters and others, including a well-known Hong Kong study, finding no benefit in any subgroup. By adding CTC status as a second, biologically grounded variable, the researchers have created a two-parameter decision tool that resolves those contradictions and matches surgical aggressiveness to the actual risk of microscopic residual disease. For a cancer that kills nearly 800,000 people each year, and where the difference between a narrow and a wide margin can determine whether a patient keeps enough liver to survive the operation—or enough liver to undergo a second operation if the tumor returns—that kind of preoperative clarity is not just a statistical finding. It is a roadmap for safer, more individualized liver cancer surgery.

Subject of Research: Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma

Article Title: Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma

Article References: Xie, J., Luo, Q., Huang, D., Xia, F., Wu, Z., Zhou, W., Zhang, Q., Tian, F., Liu, C.-Y., Xu, Z., Jiao, X.-T., Zhang, W.-Q., Ali, M., Zhou, Y., & Gao, H. (2026). Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma. Frontiers in Oncology, 16, Article 1810914. https://doi.org/10.3389/fonc.2026.1810914

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1810914

Keywords: Combined, analysis, preoperative, circulating, tumor, cells, status, size, guide, width, resection, margin

A new retrospective study from Tehran University of Medical Sciences, published in BMC Cancer, now offers one of the largest and longest-window assessments of margin outcomes in a developing country to date. Drawing on more than two decades of clinical records, the research team led by Sadaf Alipour, Bita Eslami, Nasim Nouri, Ramesh Omranipour, and Samareh Heydari analyzed the cases of 2,585 women who underwent breast-conserving surgery between 2003 and 2024. The scale of the dataset matters: with a median patient age of 49 years and a mean tumor diameter of 27 millimeters, the cohort captures the typical profile of breast cancer presentation in Iran, where disease often appears in younger women and at somewhat larger sizes than in Western registries.

The headline finding is unexpectedly encouraging. Histological examination of the surgical specimens revealed free, or negative, margins in 91.4 percent of cases, meaning that only 8.6 percent of patients had cancer cells extending to the edge of the removed tissue. That figure is lower than the rates reported in much of the existing international literature, where margin positivity after breast-conserving surgery has commonly been described at rates ranging from roughly 10 to 30 percent depending on the population, the definition of an adequate margin, and the era of the study. For a resource-constrained setting often assumed to face structural disadvantages in surgical oncology, the result challenges a persistent assumption that outcomes in developing countries must lag behind those of wealthier health systems.

The technical stakes of margin status are worth spelling out. When a pathologist examines the excised lumpectomy specimen, they ink the outer surfaces and section the tissue to determine whether tumor cells touch the inked edge. A positive margin means residual disease may remain in the breast, and the standard response is re-excision—a second operation to remove additional tissue from the involved cavity wall. Beyond the immediate burden of repeat anesthesia, hospitalization, and scarring, positive margins are associated with elevated rates of local recurrence, since any remaining tumor cells can seed regrowth. Guidelines from major surgical societies therefore treat a negative margin as a non-negotiable endpoint of breast-conserving therapy, and quality metrics in many countries track institutional re-excision rates as a proxy for surgical excellence.

Every patient in the Iranian cohort who had an involved margin underwent re-excision of the affected edge, the authors report, indicating that the clinical pathway for managing positive margins was consistently followed. That consistency itself is informative. In some low- and middle-income settings, fragmented referral pathways or limited pathology capacity can delay or complicate the identification of margin involvement. The Tehran experience suggests that a large academic center with integrated surgical and pathological services can achieve both a low primary positivity rate and reliable correction when positivity occurs, providing a template for other institutions in comparable health systems.

Perhaps the most clinically useful contribution of the study is its identification of preoperative predictors of margin involvement. Using both univariate and multivariate logistic regression models, the researchers examined how a range of tumor and patient characteristics related to the odds of a positive margin. Three factors emerged as significantly associated: younger patient age, larger tumor size, and the presence of lymphovascular invasion, the histological finding of tumor cells within small blood or lymphatic vessels surrounding the tumor. Each of these variables can be assessed before or at the time of surgery, which is precisely what makes them actionable.

The biology behind these associations is plausible. Younger patients tend to have denser breast parenchyma and, in some populations, more biologically aggressive tumor subtypes, which can make it harder for surgeons to gauge the extent of disease by palpation or imaging. Larger tumors occupy more volume relative to the breast and are more likely to have irregular, infiltrative borders that extend beyond what preoperative measurements suggest. Lymphovascular invasion, meanwhile, is a recognized marker of invasive behavior, indicating a propensity for tumor cells to spread along tissue planes—exactly the pattern that produces microscopic extensions past a grossly clear resection line. A surgeon who knows, before making the first incision, that a patient carries these risk factors can plan wider excision margins, request intraoperative assessment, or counsel the patient about the possibility of a second procedure.

The study’s methodology deserves attention for what it says about the reliability of the findings. By restricting inclusion to female patients with complete data and spanning a 21-year period, the investigators minimized the selection biases that often plague single-center surgical series. The long time window also implicitly captures the evolution of breast surgical technique over two decades, including the gradual adoption of oncoplastic approaches, improved preoperative imaging, and more standardized pathology protocols. The research was approved by the ethics committee of Tehran University of Medical Sciences and conducted with written informed consent under the Declaration of Helsinki, and the authors declare no competing interests, with funding provided by the university’s Deputy of Research.

For the global surgical oncology community, the implications cut in two directions. First, the data provide a benchmark against which other centers in developing countries can measure their own performance, filling a documented evidence gap that has made it difficult to design regionally appropriate quality-improvement programs. Second, the identified predictors give clinicians in any setting a simple, low-cost risk stratification tool: age, tumor size, and lymphovascular status are all routinely available from standard workups, requiring no advanced technology to apply. In health systems where re-operation carries disproportionate financial and logistical burdens for patients—many of whom travel long distances for care—preoperative risk prediction has an especially high practical value.

The study also serves as a reminder that surgical quality is not a function of national income alone. With careful technique, integrated pathology, and attention to known risk factors, breast-conserving surgery in a developing country can achieve margin outcomes that compare favorably with the best published figures. As the authors conclude, recognizing the clinical and pathological factors linked to margin involvement allows for better risk prediction and potential surgical adjustment before the operation begins—turning what has historically been a reactive, post-hoc problem into one that can be anticipated and, increasingly, prevented.

Subject of Research: Positive surgical margin rates and predictors in breast-conserving surgery for breast cancer in a developing country

Article Title: Frequency of positive margins and predictors in breast-conserving surgery in developing countries

Article References: Alipour, S., Eslami, B., Nouri, N., Omranipour, R., & Heydari, S. (2026). Frequency of positive margins and predictors in breast-conserving surgery in developing countries. BMC Cancer. https://doi.org/10.1186/s12885-026-17073-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17073-0

Keywords: breast cancer, breast-conserving surgery, positive surgical margin, re-excision, lymphovascular invasion, surgical oncology, Iran, risk factors, local recurrence, developing countries, tumor size, pathology

The FIGO staging system is the international standard for classifying cervical cancer, and its 2018 revision marked the most substantial overhaul in two decades. Under the previous 2009 framework, stage III disease was defined primarily by tumor extension to the pelvic sidewall or lower vagina and by hydronephrosis, while lymph node involvement was recorded separately and did not alter the stage. The 2018 revision changed that logic fundamentally. Any patient with proven pelvic or para-aortic lymph node metastasis, regardless of tumor dimensions, is now assigned to stage IIIC, subdivided into IIIC1 for pelvic nodes and IIIC2 for para-aortic involvement. The intention was to acknowledge the strong adverse prognostic weight of nodal disease and to bring imaging and pathology into the staging process, which previously relied on clinical examination alone.

That change, however, produced an unintended consequence that clinicians have been discussing ever since. A small tumor confined to the cervix with a single positive pelvic node and a bulky tumor invading the pelvic sidewall now share the same stage IIIC label, despite representing biologically and therapeutically distinct situations. Critics of the revision argued that the new category might obscure meaningful differences in outcome, complicating both treatment planning and the interpretation of clinical trials. The Mersin team, led by Hatice Banu Atay of the Department of Gynecologic Oncology, set out to quantify exactly how much heterogeneity the new system introduced and to test whether simple, routinely measured variables such as tumor diameter could restore prognostic clarity within the stage IIIC group.

The investigators retrospectively re-staged 212 consecutive patients with cervical cancer treated at Mersin University and affiliated hospitals between 2015 and 2025. After exclusions, 144 patients formed the final cohort, with a mean age of 54.5 years and a mean tumor diameter of 42.5 millimeters. Squamous cell carcinoma, the histologic type most closely linked to persistent human papillomavirus infection, accounted for 110 cases, or 76.4 percent of the cohort. From this group, 109 patients with early-stage disease under the older 2009 system, specifically stages IB and IIA/B, were analyzed in multivariate Cox regression models, while survival differences between the 2009 and 2018 stage III definitions were assessed with Kaplan-Meier curves and log-rank tests.

The survival contrast between the two staging eras was striking. Median survival for patients classified as stage III under FIGO 2009 was 26 months, whereas under the 2018 system the median survival for the corresponding stage III group rose to 74 months. The nearly threefold difference illustrates how the reclassification diluted the stage III category: patients with relatively favorable features, such as small primary tumors with limited nodal spread, were pulled into a stage that had previously been reserved for locally advanced disease. In other words, the same Roman numeral now describes a much more heterogeneous population, and the average outcome attached to that numeral has improved accordingly, without any change in the underlying biology or treatment.

Within the early-stage subgroup, tumor size emerged as the variable that mattered most. In the Cox regression analysis, each 1-millimeter increase in tumor diameter carried a hazard ratio of 1.064, with a 95 percent confidence interval of 1.022 to 1.108 and a p-value of 0.003, confirming an independent effect on mortality. Lymph node positivity, by contrast, was significant in univariate analysis but lost its independent prognostic value once tumor size and other factors were accounted for in multivariate models. This inversion of the expected hierarchy is notable, because nodal status was the principal rationale for creating stage IIIC in the first place. The authors caution, however, that the modest sample size limits the statistical power available to detect all but the strongest effects.

When the investigators stratified outcomes at the conventional 4-centimeter cutoff, the pattern became clearer. Patients assigned to stage IIIC under the 2018 system whose tumors measured 4 centimeters or smaller showed survival comparable to that of patients with stage I to II disease, while tumors larger than 4 centimeters predicted substantially worse outcomes. This observation supports the idea that the 4-centimeter boundary, which FIGO retained in its definitions of stage IB2, IB3 and IIA2, continues to separate two prognostically distinct populations even within the redefined stage IIIC. A small tumor with nodal involvement may behave far more like early-stage disease than like classic locally advanced cancer, a distinction with potential implications for how intensively such patients are treated and how they are counseled.

The authors are careful to frame these findings as hypothesis-generating rather than practice-changing. The stage IIIC subgroup with tumors of 4 centimeters or smaller contained only 11 patients, and no deaths were recorded in that group during follow-up, which makes any conclusion about its favorable prognosis inherently fragile. The retrospective, single-center design introduces further limitations, including the possibility of selection bias and variability in treatment protocols across the decade covered by the study. The team emphasizes that validation in larger, multicenter cohorts with standardized treatment regimens will be essential before any modification to staging or treatment algorithms could be considered on the basis of these results.

Even with those caveats, the study makes a meaningful contribution to an international conversation about how cervical cancer should be classified in the era of high-quality imaging and molecular profiling. By quantifying the survival gap between the 2009 and 2018 stage III definitions and by demonstrating the independent prognostic weight of tumor size, the Mersin data provide empirical support for proposals to subdivide stage IIIC further, perhaps incorporating tumor diameter as a formal staging parameter. The authors also note that their results feed into a national dataset and offer comparability with international standards, laying groundwork for future staging revisions and collaborative research. For clinicians managing cervical cancer today, the practical message is that the stage IIIC label should not be read in isolation: within it, a 3-centimeter tumor and a 7-centimeter tumor may represent very different diseases, and treatment intensity, trial stratification and prognostic counseling should reflect that reality. As cervical cancer remains a leading cause of cancer death among women worldwide, particularly in regions with limited screening infrastructure, refining the tools used to predict individual outcomes is not an academic exercise but a matter of clinical urgency.

Subject of Research: Prognostic heterogeneity of FIGO 2018 stage IIIC cervical cancer and the role of tumor size as an independent survival predictor

Article Title: Stage IIIC heterogeneity in FIGO 2018 cervical cancer staging: a retrospective single-center study on tumor size as an ındependent prognostic factor

Article References: Atay, H. B., Gokulu, S. G., Kıllı, M. C., Karagun, S., Gokay, D. Z., & Yıldırım, Y. (2026). Stage IIIC heterogeneity in FIGO 2018 cervical cancer staging: a retrospective single-center study on tumor size as an ındependent prognostic factor. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06602-w

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06602-w

Keywords: cervical cancer, FIGO 2018 staging, stage IIIC, tumor size, prognosis, lymph node metastasis, survival analysis, gynecologic oncology, Cox regression, cancer staging, squamous cell carcinoma, retrospective study